Sarcopenia Screening Allows Identifying High-Risk Patients for Allogenic Stem Cell Transplantation.

ABSTRACT: Allogenic stem cell transplantation (aSCT) is the only potentially curative treatment for high-risk hematological diseases. Despite advancements in supportive measures, aSCT outcome is still affected by considerable transplant-related mortality. We implemented a new sarcopenia assessment prior to aSCT to evaluate its predictive capability for all-cause and non-relapse mortality. Therefore all patients initially scheduled for aSCT within a 25-month period were screened during pre-transplantation-routine for muscle mass, grip strength, and aerobic capacity (AC) by measuring peak oxygen uptake (VO2peak). Patients were assigned to one of five groups adapted according current sarcopenia guidelines. Primary endpoints were all-cause and non-relapse mortality within a follow up time of up to 12 mo

SUBMITTER: Kirsten J 

PROVIDER: S-EPMC8068111 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature